How is FGL administered?
This describes how FGL is typically administered in clinical and research references, not a self-administration guide. The usual route is Subcutaneous or intranasal, on a daily schedule, generally over 2-4 weeks in animal protocols. Specific dosing is individual and beyond general information, and human evidence for FGL is limited.
Administration at a glance (reference data)
- Route: Subcutaneous or intranasal
- Schedule: Daily
- Cycle length: 2-4 weeks in animal protocols
- Half-life: Short (~hours)
References
- A synthetic NCAM-derived peptide, FGL, protects hippocampal neurons from ischemic insult both in vitro and in vivo — Skibo GG, Lushnikova IV, Voronin KY, Dmitrieva O, Novikova T, Klementiev B, Vaudano E, Berezin VA, Bock E. European Journal of Neuroscience, 2005
- The neural cell adhesion molecule-derived peptide, FGL, attenuates lipopolysaccharide-induced changes in glia in a CD200-dependent manner — Cox FF, Berezin V, Bock E, Lynch MA. Neuroscience, 2013
Pepdex is an editorial reference, not medical advice. Peptides vary in legal and approval status by country, many are research compounds without full human safety data. Talk to a qualified clinician before starting anything.
More on FGL
Last updated 2026-06-15.